Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 141,583 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 141,583 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the completion of the transaction, the chief operating officer directly owned 516,610 shares in the company, valued at $6,865,746.90. The trade was a 21.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total value of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total transaction of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total transaction of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Stock Up 5.8%

NASDAQ ADPT traded up $0.72 during trading hours on Friday, hitting $13.17. The company’s stock had a trading volume of 3,902,529 shares, compared to its average volume of 1,832,300. Adaptive Biotechnologies Corporation has a twelve month low of $6.68 and a twelve month high of $20.76. The firm has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. The stock has a fifty day moving average of $16.55 and a 200 day moving average of $15.85.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter last year, the business earned ($0.23) earnings per share. The company’s revenue was up 51.0% compared to the same quarter last year. On average, analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ADPT shares. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Guggenheim upped their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. Finally, Morgan Stanley started coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $18.25.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in Adaptive Biotechnologies during the second quarter worth $793,000. SG Americas Securities LLC increased its holdings in shares of Adaptive Biotechnologies by 53.2% in the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after purchasing an additional 12,963 shares during the last quarter. Allianz Asset Management GmbH raised its position in shares of Adaptive Biotechnologies by 305.8% in the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after purchasing an additional 242,474 shares during the period. Hillsdale Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies in the second quarter valued at about $6,618,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth about $467,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.